Australia markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
85.46-0.91 (-1.05%)
At close: 04:00PM EDT
86.50 +1.04 (+1.22%)
After hours: 07:29PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close86.37
Bid85.43 x 100
Ask85.64 x 100
Day's range85.04 - 86.31
52-week range78.02 - 125.83
Avg. volume728,264
Market cap20.595B
Beta (5Y monthly)0.23
PE ratio (TTM)167.57
EPS (TTM)0.51
Earnings date06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend date02 June 2022
1y target est114.93
  • Zacks

    Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod

    Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.

  • Business Wire

    Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union

    NEW YORK & MAINZ, Germany, June 27, 2024--Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron JN.1-adapted monovalent COVID-19 vaccine (COMIRNATY® JN.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the

  • GlobeNewswire

    BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer

    Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2 clinical data from patients with advanced or metastatic solid tumors1,2With the Fast Track designation, the development of BNT324/DB-1311 can benefit from more frequent engagement with the U.S. Food and Drug Administration (“FDA”) to support development and expedite regulatory reviewProstate cancer is